Invicta Diagnostic Ltd (INVICTA) is currently trading at 83.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Invicta Diagnostic Limited operates the consumer brand PC Diagnostics and provides integrated radiology and pathology services through a hub-and-spoke model, running eight diagnostic centres and a centralized laboratory across the Mumbai Metropolitan Region, offering advanced imaging like PET-CT, MRI, CT, sonography and a pathology menu from routine biochemistry to specialized outsourced molecular tests. During H2 FY26 the company commissioned a strategically-located Dadar centre near Tata Memorial for oncology diagnostics and is launching a South Pune hub with a 3-Tesla MRI and 128-slice cardiac CT, signalling deliberate investment into high-value imaging capabilities that can command premium realizations and specialist referral flows for Invicta Diagnostic Limited. Financially, FY26 reported total income of INR33.04 crore (up from INR30.18 crore), EBITDA of INR10.45 crore with a 31.63% margin and net profit of INR4.87 crore; H2 FY26 revenue was INR15.96 crore with EBITDA INR3.55 crore; FY26 capex cash outflow was approximately INR12.96 crore reflecting active investment in fixed assets and new centres. Radiology is the company’s core revenue driver (management indicates >90% of income), while pathology complements the patient ecosystem; management is also exploring tele-radiology and overseas pre-read services and evaluating AI for reporting efficiency, creating an asset-light adjunct vertical that could enhance utilisation and margin profile for Invicta Diagnostic Limited over time.

Over the past 52 weeks, Invicta Diagnostic Ltd has traded between a low of ₹58.10 and a high of ₹105.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Invicta Diagnostic Ltd has a market capitalization of approximately 104.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Invicta Diagnostic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 104.35 Cr, Invicta Diagnostic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Invicta Diagnostic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Invicta Diagnostic Ltd is 21.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.